Is Peritoneal Tumor Penetration of Prognostic Importance in Gastrointestinal Stromal Tumors?

  • T. HølmebakkEmail author
  • B. Bjerkehagen
  • I. V. K. Lobmaier
  • I. Hompland
  • S. Stoldt
  • K. Boye



Peritoneal tumor penetration (PP) strongly affects prognosis in gastrointestinal carcinomas. In gastrointestinal stromal tumor (GIST), its significance in the absence of tumor rupture has not been subjected to detailed analysis.


Patients undergoing complete resection for non-metastatic GIST from 2000 to 2017 were identified in the regional sarcoma database at Oslo University Hospital. Patients with extraperitoneal tumors (esophagus, rectum) or ruptured tumors were excluded from the study. Rupture was defined according to the Oslo criteria, and PP was assessed via routine histopathologic examination by sarcoma pathologists.


The study enrolled 341 patients. The median follow-up period was 51 months (range 0–175) months. In 82 (24%) of the 341 patients, PP was recorded. There were 32 recurrences, 9 in patients with PP and 23 in patients without PP. Despite statistically significant associations between PP and established risk factors (size, mitotic index, non-gastric location), the 5-year recurrence-free survival rate did not differ between the patients with PP (86%) and those without PP (90%) (hazard ratio 1.25; 95% confidence interval 0.582.70; P = 0.577). Adjuvant imatinib was administered to 53 of 97 patients in the high-risk category. The recurrence rates did not differ between the PP-positive and PP-negative patients in either group.


In GIST, PP without tumor rupture appears not to influence prognosis. This lack of prognostic significance may reflect unexplored differences between epithelial and mesenchymal malignancies.



This study was supported by the Norwegian Cancer Society (Grant 5790283 to K. Boye) and the South-East Norway Regional Health Authority (Grant 2019064 to K. Boye).

Supplementary material

10434_2019_7813_MOESM1_ESM.docx (29 kb)
Supplementary material 1 (DOCX 28 kb)


  1. 1.
    Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1992;1:341–6.CrossRefGoogle Scholar
  2. 2.
    Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, De Stefano A, Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.CrossRefGoogle Scholar
  3. 3.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:420–5.Google Scholar
  4. 4.
    Gunderson LI, Jessup JM, Sargent DJ, Greene FI, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;2:264–71.CrossRefGoogle Scholar
  5. 5.
    Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.CrossRefGoogle Scholar
  6. 6.
    Miettinen M, Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.Google Scholar
  7. 7.
    Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumour. Hum Pathol. 2008;39:1411–9.CrossRefGoogle Scholar
  8. 8.
    Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–52.CrossRefGoogle Scholar
  9. 9.
    Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74.CrossRefGoogle Scholar
  10. 10.
    Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM classification of malignant tumours (UICC). 8th ed. Oxford: Wiley; 2017.Google Scholar
  11. 11.
    Hølmebakk T, Bjerkehagen B, Boye K, Bruland O, Stoldt S, Sundby Hall K. Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. Br J Surg. 2016;103:684–91.CrossRefGoogle Scholar
  12. 12.
    Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol. 2018;25:1133–9.CrossRefGoogle Scholar
  13. 13.
    Bischof DA, Kim Y, Dodson R, et al. Conditional disease-free survival after surgical resection of gastrointestinal stromal tumours. JAMA Surg. 2015;150:299–306.CrossRefGoogle Scholar
  14. 14.
    Nishida T, Cho H, Hirota S, et al. Clinicopathological features and prognosis of primary GISTs with tumor rupture in the real world. Ann Surg Oncol. 2018;25:1961–9.CrossRefGoogle Scholar
  15. 15.
    Hølmebakk T, Bjerkehagen B, Hompland I, Stoldt S, Boye K. Relationship between R1 resection, tumour rupture, and recurrence in resected gastrointestinal stromal tumour. Br J Surg. 2019;106:419–26.CrossRefGoogle Scholar
  16. 16.
    Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumour. Ann Surg Oncol. 2007;14:2018–27.CrossRefGoogle Scholar
  17. 17.
    Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.CrossRefGoogle Scholar
  18. 18.
    Sano T, Coit DG, Kim HH, et al. Proposal of a new-stage grouping of gastric cancer for TNM classification: international gastric cancer association staging project. Gastric Cancer. 2018;20:217–25.CrossRefGoogle Scholar
  19. 19.
    Soga K, Ichikawa D, Yasukawa S, et al. Prognostic impact of the width of subserosal invasion in gastric cancer invading the subserosal layer. Surgery. 2010;2:197–203.CrossRefGoogle Scholar
  20. 20.
    Huang B, Sun Z, Wang Z, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively collected database. BMC Cancer. 2013;13:57.CrossRefGoogle Scholar
  21. 21.
    Hompes D, Tiek J, Wolthuis A, et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol. 2012;23:3123–9.CrossRefGoogle Scholar
  22. 22.
    Jayne D. Molecular biology of peritoneal carcinomatosis. In: Ceelen WP, editors. Peritoneal carcinomatosis. A multidisciplinary approach. New York: Springer; 2007.Google Scholar
  23. 23.
    Yanagimoto Y, Takahashi T, Muguruma K, et al. Reappraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2015;18:426–33.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • T. Hølmebakk
    • 1
    Email author
  • B. Bjerkehagen
    • 2
    • 3
  • I. V. K. Lobmaier
    • 2
  • I. Hompland
    • 4
  • S. Stoldt
    • 1
  • K. Boye
    • 4
  1. 1.Department of Abdominal and Pediatric SurgeryOslo University Hospital, The Norwegian Radium HospitalOsloNorway
  2. 2.Department of PathologyOslo University Hospital, The Norwegian Radium HospitalOsloNorway
  3. 3.Institute of Clinical Medicine and Institute of Oral BiologyUniversity of OsloOsloNorway
  4. 4.Department of OncologyOslo University Hospital, The Norwegian Radium HospitalOsloNorway

Personalised recommendations